Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a
leader in transforming the pharmacy care delivery model, today
announced changes to its leadership structure designed to create a
more streamlined organization with a continued focus on operational
excellence, driving continuous improvements in customer experience
and the delivery of Omnicell’s long-term commitments.
“Omnicell continues to evolve in an effort to meet the
ever-changing needs of the industry as we work to execute our
strategy to transform the pharmacy care delivery model,” said
Randall Lipps, chairman, president, chief executive officer, and
founder of Omnicell. “In recent years, we have transitioned our
business to increase our focus on ‘SaaS’ and tech-enabled services,
including launching our Advanced Services portfolio, Cloud
Platform, and Customer Success Organizations, as we seek to better
meet the needs of our customers. With these efforts complete, we
think now is the right time to reorganize our structure in a way
that we believe will best support our next chapter of evolution. I
believe these changes will enable us to operate more nimbly, drive
greater efficiencies and further strengthen our position as a
leading medication management infrastructure provider as we strive
to deliver value for our stockholders, our employees, our
healthcare partners, and their patients.”
As part of these changes, Scott Seidelmann, Executive Vice
President, Chief Commercial Officer, and Christine Mellon,
Executive Vice President, Chief Administrative and People Officer,
will step down from their respective roles, effective June 1, 2023.
Mr. Seidelmann and Ms. Mellon will remain with the Company in an
advisory role until October 2023 to help ensure a smooth
transition.
In addition, Corey Manley has been promoted to Executive Vice
President, Chief Legal and Administrative Officer, effective June
1, 2023. Mr. Manley’s expanded responsibilities will include
overseeing Omnicell’s Legal and Corporate Responsibility functions,
as well as the Company’s Human Resources/People, Employee
Environments (Real Estate), Organizational Development,
Compensation/Payroll/Benefits, Internal Communications, and Quality
organizations.
The Company also announced the following leadership
appointments, promotions, and refinement of responsibilities:
- Nish Parekh is rejoining Omnicell as Senior Vice
President, Chief Product Officer, to oversee all Global Product
Management and North America Marketing. Ms. Parekh rejoins
Omnicell, effective June 12, 2023, from AppliedVR, an immersive
therapeutics pioneer, where she served as Head of Product.
- Martha Thorne has been named as Senior Vice
President, General Manager, EnlivenHealth, effective June 19,
2023, and will be responsible for driving overall operations and
continued growth of Omnicell’s retail pharmacy business. Ms. Thorne
previously served as Chief Revenue Officer of egnite, an AI-enabled
digital health company.
- Minoo Mortazavi is being promoted to Senior Vice
President, Global Operations, with expanded responsibilities
overseeing global process optimization, along with Global Supply
Chain, the Consumables business, Customer Experience, and Customer
Technical Services.
- Jeff Schlossnagle maintains his role as Senior Vice
President, Chief Revenue Officer, overseeing the Company’s
North America Sales, Professional Services, and Specialty Pharmacy
Services teams, as well as expanded responsibilities overseeing the
Customer Success and EnlivenHealth organizations.
- Sara Dalmasso will continue serving as Senior Vice
President, General Manager of Omnicell International, with
responsibility for the Company’s international operations.
- Virad Gupta will continue serving as Senior Vice
President, Chief Technology Officer, with responsibility for
Omnicell’s Global Engineering organization.
- Maximo Rocha has been promoted to Senior Vice
President, Chief People Officer, succeeding Ms. Mellon.
“I am pleased to recognize the talent within Omnicell with these
promotions and new responsibilities and to welcome new leaders to
our organization to oversee key areas moving forward. At the same
time, I would like to thank Scott and Christine for their
dedication and significant contributions to Omnicell throughout
their tenure. Scott has played an integral role in launching our
Advanced Services portfolio and leading our transformation to an
‘as a Service’ provider. Christine has been instrumental in helping
to instill a people-first philosophy across our global enterprise.
I appreciate their willingness to stay on in advisory roles to help
ensure a smooth transition and wish them all the best in the
future,” concluded Mr. Lipps.
Mr. Manley and all of the aforementioned Senior Vice Presidents
will report directly to Mr. Lipps, except for Mr. Rocha who will
report to Mr. Manley, and Ms. Thorne, who will report to Mr.
Schlossnagle. All of the aforementioned promotions will become
effective June 1, 2023. Ms. Parekh will step into her role
effective June 12, and Ms. Thorne will step into her role effective
June 19, 2023. As previously announced, Mr. Nchacha Etta, is
joining Omnicell on June 1, 2023, as Executive Vice President,
Chief Financial Officer and will also report directly to Mr.
Lipps.
About Omnicell
Since 1992, Omnicell has been committed to transforming the
pharmacy care delivery model in an effort to optimize financial and
clinical outcomes across all settings of care. Through a
comprehensive portfolio of automation and advanced services,
Omnicell is uniquely positioned to address evolving healthcare
challenges, connect settings of care, and streamline the medication
management process. Healthcare facilities worldwide partner with
Omnicell to help increase operational efficiency, reduce medication
errors, improve patient safety, and enhance patient engagement and
adherence, helping to reduce costly hospital readmissions. To learn
more, visit omnicell.com.
From time to time, Omnicell may use the Company’s investor
relations website and other online social media channels, including
its Twitter handle www.twitter.com/omnicell, LinkedIn page
www.linkedin.com/company/omnicell, and Facebook page
www.facebook.com/omnicellinc, to disclose material non-public
information and comply with its disclosure obligations under
Regulation Fair Disclosure (“Reg FD”).
OMNICELL and the Omnicell logo are registered trademarks of
Omnicell, Inc. or one of its subsidiaries.
Forward-Looking Statements
To the extent any statements contained in this press release
deal with information that is not historical, these statements are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Without limiting the
foregoing, statements including the words “expect,” “intend,”
“may,” “will,” “should,” “would,” “could,” “plan,” “potential,”
“anticipate,” “believe,” “forecast,” “guidance,” “outlook,”
“goals,” “target,” “estimate,” “seek,” “predict,” “project,” and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are subject to the
occurrence of many events outside Omnicell’s control. Such
statements include, but are not limited to, Omnicell’s expectations
regarding the leadership and organizational appointments and
transitions, impact on business strategy and its execution,
operational improvements, and efficiencies, delivering on long-term
commitments, market position, and statements about Omnicell’s
strategy, plans, objectives, goals, and vision. Actual results and
other events may differ significantly from those contemplated by
forward-looking statements due to numerous factors that involve
substantial known and unknown risks and uncertainties. These risks
and uncertainties include, among other things, (i) unfavorable
general economic and market conditions, including the impact and
duration of inflationary pressures, (ii) ability to realize the
benefits of our expense containment efforts, (iii) Omnicell’s
ability to recruit and retain skilled and motivated personnel, (iv)
Omnicell’s ability to take advantage of growth opportunities and
develop and commercialize new solutions and enhance existing
solutions, (v) reduction in demand in the capital equipment market
or reduction in the demand for or adoption of our solutions,
systems, or services, (vi) delays in installations of our
medication management solutions or our more complex medication
packaging systems, (vii) risks related to Omnicell’s investments in
new business strategies or initiatives, including its transition to
selling more products and services on a subscription basis, and its
ability to acquire companies, businesses, or technologies and
successfully integrate such acquisitions, (viii) risks related to
failing to maintain expected service levels when providing our
Advanced Services or retaining our Advanced Services customers,
(ix) Omnicell’s ability to meet the demands of, or maintain
relationships with, its institutional, retail, and specialty
pharmacy customers, (x) continued and increased competition from
current and future competitors in the medication management
automation solutions market and the medication adherence solutions
market, and (xi) other risks and uncertainties further described in
the “Risk Factors” section of Omnicell’s most recent Annual Report
on Form 10-K, as well as in Omnicell’s other reports filed with or
furnished to the United States Securities and Exchange Commission
(“SEC”), available at www.sec.gov. Forward-looking statements
should be considered in light of these risks and uncertainties.
Investors and others are cautioned not to place undue reliance on
forward-looking statements. All forward-looking statements
contained in this press release speak only as of the date of this
press release. Omnicell assumes no obligation to update any such
statements publicly, or to update the reasons actual results could
differ materially from those expressed or implied in any
forward-looking statements, whether as a result of changed
circumstances, new information, future events, or otherwise, except
as required by law.
OMCL-E
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230530005648/en/
Kathleen Nemeth Senior Vice President, Investor Relations
Kathleen.Nemeth@omnicell.com 650-435-3318
Omnicell (NASDAQ:OMCL)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Omnicell (NASDAQ:OMCL)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024